SRR15069613
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.560
- ANGIOGENESIS+0.550
- TGF_BETA_SIGNALING+0.510
- UV_RESPONSE_DN+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- INFLAMMATORY_RESPONSE+0.460
- ALLOGRAFT_REJECTION+0.420
- IL6_JAK_STAT3_SIGNALING+0.420
- HEDGEHOG_SIGNALING+0.380
- IL2_STAT5_SIGNALING+0.380
Top 10 suppressed
- E2F_TARGETS-0.550
- OXIDATIVE_PHOSPHORYLATION-0.530
- G2M_CHECKPOINT-0.430
- DNA_REPAIR-0.410
- MYC_TARGETS_V1-0.410
- GLYCOLYSIS-0.340
- FATTY_ACID_METABOLISM-0.330
- PEROXISOME-0.300
- MTORC1_SIGNALING-0.270
- MYC_TARGETS_V2-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AN-A0FN-01A-11R-A034-07 | — | A | 0.918 |
| 2 | SRR23303737 | — | — | 0.917 |
| 3 | f22cfa82-a346-4fed-bc81-21a29bf990ee | — | — | 0.913 |
| 4 | TCGA-A2-A0T6-01A-11R-A084-07 | — | A | 0.905 |
| 5 | TCGA-78-8648-01A-11R-2403-07 | — | cohortMD2 | 0.901 |
| 6 | TCGA-CV-6934-01A-11R-1915-07 | — | — | 0.898 |
| 7 | GSM6454738 | — | A | 0.897 |
| 8 | C3N-02923 | — | cohortMD2 | 0.896 |
| 9 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.896 |
| 10 | TCGA-D8-A141-01A-11R-A115-07 | — | A | 0.896 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.560 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.550 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.510 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.490 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.380 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| MYOGENESIS | 0.150 | Inavolisib | — uncovered |